Navigation Links
Combination Drugs are the Future of the European Hepatitis B and C Therapeutics Markets, Says Frost & Sullivan
Date:5/1/2013

LONDON, May 1, 2013 /PRNewswire/ -- The limited efficacy and negative side-effects associated with current therapeutics for Hepatitis B and C are highlighting the urgent need for new, improved alternatives. Combination therapies offering better clinical outcomes are coming to the fore and look set to transform the European market for Hepatitis B and C.

New analysis from Frost & Sullivan (http://www.lifesciences.frost.com), Analysis of European Hepatitis B and C Therapeutics Markets, finds that the Hepatitis B market earned revenues of $1.26 billion in 2012 and estimates this to reach $1.89 billion in 2019, while the Hepatitis C market is projected to expand from $2.40 billion to $3.66 billion over the same time period. The therapeutic segments covered include interferons and nucleoside analogues for Hepatitis B, and Standard of Care (Peginterferon alfa and Ribavirin) and protease inhibitors for Hepatitis C.

The side-effects associated with interferon-based therapeutics – such as fever, headache, fatigue, muscle and joint pain, shivering, and the ineffective response to Hepatitis C Virus (HCV) genotype 1 patients – are motivating the development of combination therapies.

"Improved drug efficiency, reduced pill burden and lower dosage frequency are among the common advantages related to the use of combination drugs," notes Frost & Sullivan Healthcare Research Analyst Deepika Pramod Chopda . "For instance, the combined use of interferon and interferon-free treatments is expected to yield positive results among infected patients; ribavirin-long acting interferons combination is estimated to boost the therapeutic success rate by over 50-60%."

The market is responding swiftly to the demand for improved therapeutic offerings. There has been an increase in new classes of compounds such as protease inhibitors
'/>"/>

SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
2. Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma
3. Medivir Announces an Interferon-Free Phase II Combination Trial With TMC435 and daclatasvir to Commence Shortly
4. Multi-Targeted Therapies - New Wave of Combination Therapies in Late Stage Development for Lung Cancer Offer Promise
5. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
6. American Journal of Medicine Publishes Hypertension Study Comparing the Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone versus Azilsartan Medoxomil Co-administered with Hydrochlorothiazide
7. Hagens Berman Sobol Shapiro LLP and Douglas & London P.C. Announce Proposed Class Action Settlement in Bayer Combination Aspirin Products Litigation
8. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
9. Scottsdale Healthcare, TGen study shows Abraxane/gemcitabine combination extends survival of pancreatic cancer patients
10. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
11. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... British Columbia, March 26, 2015  OncoGenex Pharmaceuticals, ... summary of clinical developments and announced fourth quarter ... Clinical Developments and Anticipated Near-term MilestonesCustirsen ... Teva agreed to negotiate the termination of their ... of the final termination agreement are ongoing. ...
(Date:3/26/2015)... 2015 Over-the-counter healthcare costs can be ... a new survey of store brand over-the-counter products ... cold to diabetes, can offer significant savings for ... the Private Label Manufacturers Association, assembled a market ... those essential for treatment of pre-diabetes and diabetes. ...
(Date:3/26/2015)... PLEASANTON, Calif. , March 26, 2015  Desert ... the Nation five times , is the first ... System in its emergency department to help clinicians prevent ... in Victorville, Calif. , is a ... and bariatric patients.  Using the Leaf Patient Monitor in ...
Breaking Medicine Technology:OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8Consumers can keep over-the-counter medicine affordable by using store brands 2Desert Valley Medical Center First to Use Leaf Healthcare Patient Wearable Technology in its ED as Part of Hospital-wide Deployment 2Desert Valley Medical Center First to Use Leaf Healthcare Patient Wearable Technology in its ED as Part of Hospital-wide Deployment 3
... , ATLANTA and STOCKHOLM , ... (1907-1986), inventor of the radiosurgical instrument that bears his ... (Solna, Sweden ), performed the world,s first ... location of the first Leksell Gamma Knife. Karolinska University ...
... April 23 Yesterday, T he Lancet ... once-daily human GLP-1 analog, Victoza® (liraglutide [rDNA] injection) with a DPP-4 ... reductions in A1C, fasting plasma glucose (FPG), and body weight than ... , , ...
Cached Medicine Technology:Karolinska University Hospital Acquires Leksell Gamma Knife Perfexion to Expand Radiosurgery Versatility, Efficiency in Brain Cancer Therapy 2Karolinska University Hospital Acquires Leksell Gamma Knife Perfexion to Expand Radiosurgery Versatility, Efficiency in Brain Cancer Therapy 3The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes 2The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes 3The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes 4The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes 5The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes 6
(Date:3/26/2015)... Let’s not lose focus of why people ... traffic magnets. Three out of 4 consumers choose to ... department, according to a Packaged Facts survey. Produce Managers ... to add more fruits and vegetables to their lifestyle. ... April 2. As featured in the Chase’s Calendar of ...
(Date:3/26/2015)... March 26, 2015 UC Davis will ... into the origins of schizophrenia: A Silvio O. Conte ... only 15 such centers in the United States. , ... grant from the National Institutes of Mental Health, which ... novel hypothesis that an origin of schizophrenia may be ...
(Date:3/26/2015)... York, New York (PRWEB) March 26, 2015 ... continue to move forward nationwide, with the issuance ... underway in Pennsylvania and Louisiana. According to an ... federal multidistrict litigation established for Xarelto injury claims ... Louisiana will now allow plaintiffs to file cases ...
(Date:3/26/2015)... DC (PRWEB) March 26, 2015 “The SWEET ... to make healthy options more available and help parents who ... penny tax is a reasonable approach to support public health, ... of this issue for the health of all families,” said ... for Hispanic Health on the introduction of the Sugar-Sweetened Beverage ...
(Date:3/26/2015)... CA (PRWEB) March 26, 2015 Dr. ... are proud to announce expanded offerings for Bay Area ... Francisco Dental Implant Center has long been a top-rated ... expanded its offerings to meet the strong demand by ... our reputation as a top-rated dental implant facility in ...
Breaking Medicine News(10 mins):Health News:UC Davis Receives $10 Million Grant to Establish Center to Study Schizophrenia 2Health News:UC Davis Receives $10 Million Grant to Establish Center to Study Schizophrenia 3Health News:UC Davis Receives $10 Million Grant to Establish Center to Study Schizophrenia 4Health News:Xarelto Lawsuits Move Forward Nationwide, With Issuance of New Court Docs in State, Federal Litigations 2Health News:Xarelto Lawsuits Move Forward Nationwide, With Issuance of New Court Docs in State, Federal Litigations 3Health News:National Alliance for Hispanic Health Statement on Introduction of SWEET Act in 114th Congress 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 3
... WASHINGTON, Oct. 4 Michael J. Fitzpatrick,executive director ... today,thanked Senator Pete Domenici (New Mexico) for his ... statement followed the senator,s,announcement of his intention to ... 35 years in the nation,s capital, Senator Pete ...
... Oct. 4 Biomoda, Inc. (OTC,Bulletin Board: BMOD) ... lung cancer detection testing and other cancer diagnostic ... of,Southborough, Mass. to provide a range of clinical ... clinical programs. "Averion is a global clinical ...
... The Hartford Center for Geriatric Nursing Excellence in the ... Hartford centers in the nation, have been funded for ... have the most recent evidence-based guidelines for caring for ... Centers of Geriatric Nursing Excellence, which will form the ...
... National IPF Awareness Week on Capitol Hill Drives,Efforts ... SAN JOSE, Calif., Oct. 4 The ... success of its fifth,annual National IPF Awareness Week, ... about the critical need to fund new research ...
... N.J., Oct. 4 The following is a,statement regarding ... health information online:, It is encouraging that companies ... personal health record (PHR) products and systems,that people can ... more companies will follow suit. Having ready access to ...
... MedImmune, Inc. today announced results from two important studies ... (IDSA) 45th Annual Meeting adding to the body of ... a viral pathogen that produces annual outbreaks usually between ... in healthy children, it can prove to be a ...
Cached Medicine News:Health News:Biomoda and Averion International Announce Agreement for Clinical Services 2Health News:CPF Urges Congress to Increase Funding for IPF Research in 2009 Federal Budget 2Health News:CPF Urges Congress to Increase Funding for IPF Research in 2009 Federal Budget 3Health News:CPF Urges Congress to Increase Funding for IPF Research in 2009 Federal Budget 4Health News:Statement Regarding Microsoft's Announcement of New Services to Help People Store Their Health Information Online 2Health News:Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results 2
Maddox Rod, long handle...
... Snellen chart remains to most popular ... of different optotypes can be displayed ... landolt Cs, tumbling Es and kaye ... can be shown and a range ...
Snellen 10' Eye Test Chart....
... The Accutome Ultrasound Advent Pachymeter exceeds ... elements: For ALK and other lamellar procedures, ... to 90 microns. High end range is ... general patient care. Newly designed 55 angle ...
Medicine Products: